Efficacy of selective serotonin reuptake inhibitors-related antidepressants in Alzheimer's disease: a meta-analysis.
Alzheimer’s disease
Antidepressants
Cognitive improvement
SSRIs
Therapeutic efficacy
Journal
European journal of medical research
ISSN: 2047-783X
Titre abrégé: Eur J Med Res
Pays: England
ID NLM: 9517857
Informations de publication
Date de publication:
29 Aug 2024
29 Aug 2024
Historique:
received:
28
05
2024
accepted:
31
07
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
29
8
2024
Statut:
epublish
Résumé
To study the effects of selective serotonin reuptake inhibitors (SSRIs) on cognitive functions, mental improvements, and adverse effects in patients with Alzheimer's disease (AD). Registered in INPLASY (INPLASY202450004), five drugs (citalopram, s-citalopram, quetiapine, olanzapine, and sertraline) were selected as representatives. A comprehensive search was conducted in PubMed, EMBASE, Web of Science, and the Cochrane Library up to May 15, 2024. Search terms were combined using Boolean operators, specifically 'AND' between different categories (e.g., 'Alzheimer's Disease' AND 'SSRIs') and 'OR' within the same category (e.g., 'citalopram OR s-citalopram OR quetiapine OR olanzapine OR sertraline'), to ensure a thorough retrieval of relevant studies. The selection followed rigorous inclusion and exclusion criteria for meta-analysis. Fourteen articles from 1118 were selected for meta-analysis. The indicators, including Neuropsychiatric Inventory (NPI), Mini-Mental State Examination (MMSE), Brief Psychiatric Rating Scale (BPRS), and Cornell Scale for Depression in Dementia (CSDD), were used to assess the effects of the drugs on AD treatment. According to the results of NPI, CSDD, BPRS, MMSE, and security assessments, the five antidepressants have significant advantages in AD treatment compared with placebo, while the MMSE of the patient treated with the antidepressants did not show notable changes compared with patients treated only with placebo. Statistical analyses were conducted using Review Manager 5.3, employing random-effects models to account for study heterogeneity and sensitivity analyses to test the robustness of our findings. This study suggests that SSRI-related antidepressants have great potential values in AD treatment, and further research on the application of SSRI-related antidepressants in AD treatment is necessary.
Identifiants
pubmed: 39210432
doi: 10.1186/s40001-024-02006-z
pii: 10.1186/s40001-024-02006-z
doi:
Substances chimiques
Selective Serotonin Reuptake Inhibitors
0
Antidepressive Agents
0
Citalopram
0DHU5B8D6V
Sertraline
QUC7NX6WMB
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
438Informations de copyright
© 2024. The Author(s).
Références
Jiang S, Yang Y, Li T, Ma Z, Hu W, Deng C, et al. An overview of the mechanisms and novel roles of Nrf2 in cardiovascular diseases. Expert Opin Ther Targets. 2016;20(12):1413–24. https://doi.org/10.1080/14728222.2016.1250887 .
doi: 10.1080/14728222.2016.1250887
pubmed: 27756179
Li T, Providencia R, Mu N, Yin Y, Chen M, Wang Y, et al. Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2021;20(1):30. https://doi.org/10.1186/s12933-020-01202-5 .
doi: 10.1186/s12933-020-01202-5
pubmed: 33516224
pmcid: 7847575
Li T, Mu N, Yin Y, Yu L, Ma H. Targeting AMP-activated protein kinase in aging-related cardiovascular diseases. Aging Dis. 2020;11(4):967–77. https://doi.org/10.14336/ad.2019.0901 .
doi: 10.14336/ad.2019.0901
pubmed: 32765957
pmcid: 7390518
Li X, Liu L, Li T, Liu M, Wang Y, Ma H, et al. SIRT6 in senescence and aging-related cardiovascular diseases. Front Cell Dev Biol. 2021;9: 641315. https://doi.org/10.3389/fcell.2021.641315 .
doi: 10.3389/fcell.2021.641315
pubmed: 33855020
pmcid: 8039379
Du MR, Gao QY, Liu CL, Bai LY, Li T, Wei FL. Exploring the pharmacological potential of metformin for neurodegenerative diseases. Front Aging Neurosci. 2022;14: 838173. https://doi.org/10.3389/fnagi.2022.838173 .
doi: 10.3389/fnagi.2022.838173
pubmed: 35557834
pmcid: 9087341
Shi L, Zhang R, Li T, Han X, Yuan N, Jiang L, et al. Decreased miR-132 plays a crucial role in diabetic encephalopathy by regulating the GSK-3β/Tau pathway. Aging (Albany NY). 2020;13(3):4590–604. https://doi.org/10.18632/aging.202418 .
doi: 10.18632/aging.202418
pubmed: 33406505
Zhang F, Liu L, Zhang C, Ji S, Mei Z, Li T. Association of metabolic syndrome and its components with risk of stroke recurrence and mortality: a meta-analysis. Neurology. 2021;97(7):e695–705. https://doi.org/10.1212/wnl.0000000000012415 .
doi: 10.1212/wnl.0000000000012415
pubmed: 34321360
Wang S, Fan Y, Feng X, Sun C, Shi Z, Li T, et al. Nicorandil alleviates myocardial injury and post-infarction cardiac remodeling by inhibiting Mst1. Biochem Biophys Res Commun. 2018;495(1):292–9. https://doi.org/10.1016/j.bbrc.2017.11.041 .
doi: 10.1016/j.bbrc.2017.11.041
pubmed: 29127009
Ning P, Luo A, Mu X, Xu Y, Li T. Exploring the dual character of metformin in Alzheimer’s disease. Neuropharmacology. 2022;207: 108966. https://doi.org/10.1016/j.neuropharm.2022.108966 .
doi: 10.1016/j.neuropharm.2022.108966
pubmed: 35077762
Liao W, Xu J, Li B, Ruan Y, Li T, Liu J. Deciphering the roles of metformin in Alzheimer’s disease: a snapshot. Front Pharmacol. 2021;12: 728315. https://doi.org/10.3389/fphar.2021.728315 .
doi: 10.3389/fphar.2021.728315
pubmed: 35153733
Möllers T, Perna L, Stocker H, Ihle P, Schubert I, Schöttker B, et al. Alzheimer’s disease medication and outcomes of hospitalisation among patients with dementia. Epidemiol Psychiatr Sci. 2019;29: e73. https://doi.org/10.1017/s2045796019000702 .
doi: 10.1017/s2045796019000702
pubmed: 31722770
pmcid: 8060969
Younan D, Petkus AJ, Widaman KF, Wang X, Casanova R, Espeland MA, et al. Particulate matter and episodic memory decline mediated by early neuroanatomic biomarkers of Alzheimer’s disease. Brain. 2020;143(1):289–302. https://doi.org/10.1093/brain/awz348 .
doi: 10.1093/brain/awz348
pubmed: 31746986
Nicoll JAR, Buckland GR, Harrison CH, Page A, Harris S, Love S, et al. Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer’s disease. Brain. 2019;142(7):2113–26. https://doi.org/10.1093/brain/awz142 .
doi: 10.1093/brain/awz142
pubmed: 31157360
pmcid: 6598630
Herbert J, Lucassen PJ. Depression as a risk factor for Alzheimer’s disease: genes, steroids, cytokines and neurogenesis—what do we need to know? Front Neuroendocrinol. 2016;41:153–71. https://doi.org/10.1016/j.yfrne.2015.12.001 .
doi: 10.1016/j.yfrne.2015.12.001
pubmed: 26746105
Xu J, Li Q, Qin W, Jun Li M, Zhuo C, Liu H, et al. Neurobiological substrates underlying the effect of genomic risk for depression on the conversion of amnestic mild cognitive impairment. Brain. 2018;141(12):3457–71. https://doi.org/10.1093/brain/awy277 .
doi: 10.1093/brain/awy277
pubmed: 30445590
pmcid: 6693294
Qiu Y, Jacobs DM, Messer K, Salmon DP, Feldman HH. Cognitive heterogeneity in probable Alzheimer disease: clinical and neuropathologic features. Neurology. 2019;93(8):e778–90. https://doi.org/10.1212/wnl.0000000000007967 .
doi: 10.1212/wnl.0000000000007967
pubmed: 31320469
pmcid: 6711663
Peineau S, Rabiant K, Pierrefiche O, Potier B. Synaptic plasticity modulation by circulating peptides and metaplasticity: involvement in Alzheimer’s disease. Pharmacol Res. 2018;130:385–401. https://doi.org/10.1016/j.phrs.2018.01.018 .
doi: 10.1016/j.phrs.2018.01.018
pubmed: 29425728
Mackin RS, Insel PS, Landau S, Bickford D, Morin R, Rhodes E, et al. Late-life depression is associated with reduced cortical amyloid burden: findings from the Alzheimer’s disease neuroimaging initiative depression project. Biol Psychiatry. 2021;89(8):757–65. https://doi.org/10.1016/j.biopsych.2020.06.017 .
doi: 10.1016/j.biopsych.2020.06.017
pubmed: 32980132
Bartels C, Wagner M, Wolfsgruber S, Ehrenreich H, Schneider A. Impact of SSRI therapy on risk of conversion from mild cognitive impairment to Alzheimer’s dementia in individuals with previous depression. Am J Psychiatry. 2018;175(3):232–41. https://doi.org/10.1176/appi.ajp.2017.17040404 .
doi: 10.1176/appi.ajp.2017.17040404
pubmed: 29179578
Ai PH, Chen S, Liu XD, Zhu XN, Pan YB, Feng DF, et al. Paroxetine ameliorates prodromal emotional dysfunction and late-onset memory deficit in Alzheimer’s disease mice. Transl Neurodegener. 2020;9(1):18. https://doi.org/10.1186/s40035-020-00194-2 .
doi: 10.1186/s40035-020-00194-2
pubmed: 32398165
pmcid: 7216685
He S, Li Y, Li T, Xu F, Zeng D, Shi Y, et al. Sex differences between serum total bilirubin levels and cognition in patients with schizophrenia. BMC Psychiatry. 2021;21(1):396. https://doi.org/10.1186/s12888-021-03407-8 .
doi: 10.1186/s12888-021-03407-8
pubmed: 34376171
pmcid: 8353745
Gao K, Ma WZ, Huck S, Li BL, Zhang L, Zhu J, et al. Association between sarcopenia and depressive symptoms in Chinese older adults: evidence from the China Health and retirement longitudinal study. Front Med (Lausanne). 2021;8: 755705. https://doi.org/10.3389/fmed.2021.755705 .
doi: 10.3389/fmed.2021.755705
pubmed: 34869454
He S, Deng Z, Li Z, Gao W, Zeng D, Shi Y, et al. Signatures of 4 autophagy-related genes as diagnostic markers of MDD and their correlation with immune infiltration. J Affect Disord. 2021;295:11–20. https://doi.org/10.1016/j.jad.2021.08.005 .
doi: 10.1016/j.jad.2021.08.005
pubmed: 34391068
von Linstow CU, Waider J, Grebing M, Metaxas A, Lesch KP, Finsen B. Serotonin augmentation therapy by escitalopram has minimal effects on amyloid-β levels in early-stage Alzheimer’s-like disease in mice. Alzheimers Res Ther. 2017;9(1):74. https://doi.org/10.1186/s13195-017-0298-y .
doi: 10.1186/s13195-017-0298-y
Cirrito JR, Wallace CE, Yan P, Davis TA, Gardiner WD, Doherty BM, et al. Effect of escitalopram on Aβ levels and plaque load in an Alzheimer mouse model. Neurology. 2020;95(19):e2666–74. https://doi.org/10.1212/wnl.0000000000010733 .
doi: 10.1212/wnl.0000000000010733
pubmed: 32913022
pmcid: 7713734
Sheline YI, West T, Yarasheski K, Swarm R, Jasielec MS, Fisher JR, et al. An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice. Sci Transl Med. 2014;6(236):23re64. https://doi.org/10.1126/scitranslmed.3008169 .
doi: 10.1126/scitranslmed.3008169
Sheline YI, Snider BJ, Beer JC, Seok D, Fagan AM, Suckow RF, et al. Effect of escitalopram dose and treatment duration on CSF Aβ levels in healthy older adults: a controlled clinical trial. Neurology. 2020;95(19):e2658–65. https://doi.org/10.1212/wnl.0000000000010725 .
doi: 10.1212/wnl.0000000000010725
pubmed: 32913021
pmcid: 7713735
Cirrito JR, Disabato BM, Restivo JL, Verges DK, Goebel WD, Sathyan A, et al. Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans. Proc Natl Acad Sci USA. 2011;108(36):14968–73. https://doi.org/10.1073/pnas.1107411108 .
doi: 10.1073/pnas.1107411108
pubmed: 21873225
pmcid: 3169155
Locher C, Koechlin H, Zion SR, Werner C, Pine DS, Kirsch I, et al. Efficacy and safety of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and placebo for common psychiatric disorders among children and adolescents: a systematic review and meta-analysis. JAMA Psychiat. 2017;74(10):1011–20. https://doi.org/10.1001/jamapsychiatry.2017.2432 .
doi: 10.1001/jamapsychiatry.2017.2432
Vangala C, Niu J, Montez-Rath ME, Yan J, Navaneethan SD, Winkelmayer WC. Selective serotonin reuptake inhibitor use and hip fracture risk among patients on hemodialysis. Am J Kidney Dis. 2020;75(3):351–60. https://doi.org/10.1053/j.ajkd.2019.07.015 .
doi: 10.1053/j.ajkd.2019.07.015
pubmed: 31606233
Laporte S, Chapelle C, Caillet P, Beyens MN, Bellet F, Delavenne X, et al. Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: a meta-analysis of observational studies. Pharmacol Res. 2017;118:19–32. https://doi.org/10.1016/j.phrs.2016.08.017 .
doi: 10.1016/j.phrs.2016.08.017
pubmed: 27521835
Guze SB. Diagnostic and statistical manual of mental disorders, 4th ed. (DSM-IV). Am J Psychiatry. 1995;152(8):1228. https://doi.org/10.1176/ajp.152.8.1228 .
doi: 10.1176/ajp.152.8.1228
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology. 1984;34(7):939–44. https://doi.org/10.1212/wnl.34.7.939 .
doi: 10.1212/wnl.34.7.939
pubmed: 6610841
Hou M, Xing H, Li C, Wang X, Deng D, Li J, et al. Short-term efficacy and safety of lasmiditan, a novel 5-HT(1F) receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis. J Headache Pain. 2020;21(1):66. https://doi.org/10.1186/s10194-020-01138-x .
doi: 10.1186/s10194-020-01138-x
pubmed: 32503415
pmcid: 7275414
Zhou T, Wang J, Xin C, Kong L, Wang C. Effect of memantine combined with citalopram on cognition of BPSD and moderate Alzheimer’s disease: a clinical trial. Exp Ther Med. 2019;17(3):1625–30. https://doi.org/10.3892/etm.2018.7124 .
doi: 10.3892/etm.2018.7124
pubmed: 30783429
An H, Choi B, Park KW, Kim DH, Yang DW, Hong CH, et al. The effect of escitalopram on mood and cognition in depressive Alzheimer’s disease subjects. J Alzheimers Dis. 2017;55(2):727–35. https://doi.org/10.3233/jad-160225 .
doi: 10.3233/jad-160225
pubmed: 27716660
Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Depression and Alzheimer’s disease: symptom or comorbidity? Am J Alzheimers Dis Other Demen. 2002;17(6):338–44. https://doi.org/10.1177/153331750201700607 .
doi: 10.1177/153331750201700607
pubmed: 12501480
pmcid: 10833988
Finkel SI, Mintzer JE, Dysken M, Krishnan KR, Burt T, McRae T. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer’s disease in outpatients treated with donepezil. Int J Geriatr Psychiatry. 2004;19(1):9–18. https://doi.org/10.1002/gps.998 .
doi: 10.1002/gps.998
pubmed: 14716694
Paleacu D, Barak Y, Mirecky I, Mazeh D. Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer’s disease patients: a 6-week, double-blind, placebo-controlled study. Int J Geriatr Psychiatry. 2008;23(4):393–400. https://doi.org/10.1002/gps.1892 .
doi: 10.1002/gps.1892
pubmed: 17879256
Lyketsos CG, DelCampo L, Steinberg M, Miles Q, Steele CD, Munro C, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry. 2003;60(7):737–46. https://doi.org/10.1001/archpsyc.60.7.737 .
doi: 10.1001/archpsyc.60.7.737
pubmed: 12860778
Kurlan R, Cummings J, Raman R, Thal L. Quetiapine for agitation or psychosis in patients with dementia and Parkinsonism. Neurology. 2007;68(17):1356–63. https://doi.org/10.1212/01.wnl.0000260060.60870.89 .
doi: 10.1212/01.wnl.0000260060.60870.89
pubmed: 17452579
Tariot PN, Schneider L, Katz IR, Mintzer JE, Street J, Copenhaver M, et al. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry. 2006;14(9):767–76. https://doi.org/10.1097/01.Jgp.0000196628.12010.35 .
doi: 10.1097/01.Jgp.0000196628.12010.35
pubmed: 16905684
Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer’s disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008;165(7):844–54. https://doi.org/10.1176/appi.ajp.2008.07111779 .
doi: 10.1176/appi.ajp.2008.07111779
pubmed: 18519523
pmcid: 2714365
Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682–91. https://doi.org/10.1001/jama.2014.93 .
doi: 10.1001/jama.2014.93
pubmed: 24549548
pmcid: 4086818
Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry. 2000;57(10):968–76. https://doi.org/10.1001/archpsyc.57.10.968 .
doi: 10.1001/archpsyc.57.10.968
pubmed: 11015815
Deberdt WG, Dysken MW, Rappaport SA, Feldman PD, Young CA, Hay DP, et al. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry. 2005;13(8):722–30. https://doi.org/10.1176/appi.ajgp.13.8.722 .
doi: 10.1176/appi.ajgp.13.8.722
pubmed: 16085789
Hamelin L, Lagarde J, Dorothée G, Potier MC, Corlier F, Kuhnast B, et al. Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer’s disease. Brain. 2018;141(6):1855–70. https://doi.org/10.1093/brain/awy079 .
doi: 10.1093/brain/awy079
pubmed: 29608645
Dubois B, Epelbaum S, Nyasse F, Bakardjian H, Gagliardi G, Uspenskaya O, et al. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer’s disease (INSIGHT-preAD): a longitudinal observational study. Lancet Neurol. 2018;17(4):335–46. https://doi.org/10.1016/s1474-4422(18)30029-2 .
doi: 10.1016/s1474-4422(18)30029-2
pubmed: 29500152
Munro CA, Brandt J, Sheppard JM, Steele CD, Samus QM, Steinberg M, et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: secondary outcomes from the depression in Alzheimer’s disease study (DIADS). Am J Geriatr Psychiatry. 2004;12(5):491–8. https://doi.org/10.1176/appi.ajgp.12.5.491 .
doi: 10.1176/appi.ajgp.12.5.491
pubmed: 15353387
Li DD, Zhang YH, Zhang W, Zhao P. Meta-analysis of randomized controlled trials on the efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease. Front Neurosci. 2019;13:472. https://doi.org/10.3389/fnins.2019.00472 .
doi: 10.3389/fnins.2019.00472
pubmed: 31156366
pmcid: 6529534
Bucki A, Marcinkowska M, Śniecikowska J, Zagórska A, Jamrozik M, Pawłowski M, et al. Multifunctional 6-fluoro-3-[3-(pyrrolidin-1-yl)propyl]-1,2-benzoxazoles targeting behavioral and psychological symptoms of dementia (BPSD). Eur J Med Chem. 2020;191: 112149. https://doi.org/10.1016/j.ejmech.2020.112149 .
doi: 10.1016/j.ejmech.2020.112149
pubmed: 32105980
Geerts H, Spiros A. Simulating the effects of common comedications and genotypes on Alzheimer’s cognitive trajectory using a quantitative systems pharmacology approach. J Alzheimers Dis. 2020;78(1):413–24. https://doi.org/10.3233/jad-200688 .
doi: 10.3233/jad-200688
pubmed: 33016912
Takemoto M, Ohta Y, Hishikawa N, Yamashita T, Nomura E, Tsunoda K, et al. The efficacy of sertraline, escitalopram, and nicergoline in the treatment of depression and apathy in Alzheimer’s disease: the Okayama depression and apathy project (ODAP). J Alzheimers Dis. 2020;76(2):769–72. https://doi.org/10.3233/jad-200247 .
doi: 10.3233/jad-200247
pubmed: 32568205
Moriguchi S, Takahata K, Shimada H, Kubota M, Kitamura S, Kimura Y, et al. Excess tau PET ligand retention in elderly patients with major depressive disorder. Mol Psychiatry. 2021;26(10):5856–63. https://doi.org/10.1038/s41380-020-0766-9 .
doi: 10.1038/s41380-020-0766-9
pubmed: 32606373
Baek SH, Park SJ, Jeong JI, Kim SH, Han J, Kyung JW, et al. Inhibition of Drp1 ameliorates synaptic depression, Aβ deposition, and cognitive impairment in an Alzheimer’s disease model. J Neurosci. 2017;37(20):5099–110. https://doi.org/10.1523/jneurosci.2385-16.2017 .
doi: 10.1523/jneurosci.2385-16.2017
pubmed: 28432138
pmcid: 6596467
Fišar Z, Hansíková H, Křížová J, Jirák R, Kitzlerová E, Zvěřová M, et al. Activities of mitochondrial respiratory chain complexes in platelets of patients with Alzheimer’s disease and depressive disorder. Mitochondrion. 2019;48:67–77. https://doi.org/10.1016/j.mito.2019.07.013 .
doi: 10.1016/j.mito.2019.07.013
pubmed: 31377247
Chen B, Zhong X, Mai N, Peng Q, Wu Z, Ouyang C, et al. Cognitive impairment and structural abnormalities in late life depression with olfactory identification impairment: an Alzheimer’s disease-like pattern. Int J Neuropsychopharmacol. 2018;21(7):640–8. https://doi.org/10.1093/ijnp/pyy016 .
doi: 10.1093/ijnp/pyy016
pubmed: 29554341
pmcid: 6030850
Paroni G, Panza F, De Cosmo S, Greco A, Seripa D, Mazzoccoli G. Klotho at the edge of Alzheimer’s disease and senile depression. Mol Neurobiol. 2019;56(3):1908–20. https://doi.org/10.1007/s12035-018-1200-z .
doi: 10.1007/s12035-018-1200-z
pubmed: 29978424
Zhang Q, Yang C, Liu T, Liu L, Li F, Cai Y, et al. Citalopram restores short-term memory deficit and non-cognitive behaviors in APP/PS1 mice while halting the advance of Alzheimer’s disease-like pathology. Neuropharmacology. 2018;131:475–86. https://doi.org/10.1016/j.neuropharm.2017.12.021 .
doi: 10.1016/j.neuropharm.2017.12.021
pubmed: 29241655
Tin G, Mohamed T, Shakeri A, Pham AT, Rao PPN. Interactions of selective serotonin reuptake inhibitors with β-amyloid. ACS Chem Neurosci. 2019;10(1):226–34. https://doi.org/10.1021/acschemneuro.8b00160 .
doi: 10.1021/acschemneuro.8b00160
pubmed: 30157623
Cummings J. The role of biomarkers in Alzheimer’s disease drug development. Adv Exp Med Biol. 2019;1118:29–61. https://doi.org/10.1007/978-3-030-05542-4_2 .
doi: 10.1007/978-3-030-05542-4_2
pubmed: 30747416
pmcid: 6750734
Berman MH, Nichols TW. Treatment of neurodegeneration: integrating photobiomodulation and neurofeedback in Alzheimer’s dementia and Parkinson’s: a review. Photobiomodul Photomed Laser Surg. 2019;37(10):623–34. https://doi.org/10.1089/photob.2019.4685 .
doi: 10.1089/photob.2019.4685
pubmed: 31647776
Porsteinsson AP, Antonsdottir IM. An update on the advancements in the treatment of agitation in Alzheimer’s disease. Expert Opin Pharmacother. 2017;18(6):611–20. https://doi.org/10.1080/14656566.2017.1307340 .
doi: 10.1080/14656566.2017.1307340
pubmed: 28300462
Szabó L, Mile V, Kiss DJ, Kovács K, Földes T, Németh T, et al. Applicability evaluation of advanced processes for elimination of neurophysiological activity of antidepressant fluoxetine. Chemosphere. 2018;193:489–97. https://doi.org/10.1016/j.chemosphere.2017.11.047 .
doi: 10.1016/j.chemosphere.2017.11.047
pubmed: 29156334
Jacobsen JP, Rudder ML, Roberts W, Royer EL, Robinson TJ, Oh A, et al. SSRI augmentation by 5-hydroxytryptophan slow release: mouse pharmacodynamic proof of concept. Neuropsychopharmacology. 2016;41(9):2324–34. https://doi.org/10.1038/npp.2016.35 .
doi: 10.1038/npp.2016.35
pubmed: 26932820
pmcid: 4946063